Insider · CIK 0001559706
Slate Path Capital LP
Files at KRSA (Cyclerion Therapeutics, Inc.). First filing Nov 25, 2024, latest Nov 25, 2024.
Slate Path Capital LP files SEC Form 4 as 10% owner at KRSA (Cyclerion Therapeutics, Inc.). Since Nov 25, 2024, Slate Path Capital LP has reported 0 open-market buys worth $0 and 1 open-market sell worth $555k, the latest filed on Nov 25, 2024.
A track record needs three past buys with six months of prices behind them; Slate Path Capital LP has 0, so none is measured yet.
The newest scored trade: sold $555k of KRSA on Nov 21, 2024, filed Nov 25, 2024, scored 51 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | KRSAsell Cyclerion Therapeutics, Inc. | $555k 357,880 shares | -100% | - |
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 21, 2024 | KRSA Cyclerion Therapeutics, Inc. | SOpen-market sale Common Stock, no par valueindirect: See footnote | -357,880 | $1.55 | $555k | 0 | Nov 25, 2024 |
Questions about Slate Path Capital LP
Answered from the filings on this page, as of the latest one.
Is Slate Path Capital LP buying or selling?
Not in the last 12 months. Slate Path Capital LP's latest open-market trade on SEC Form 4 was sold $555k of KRSA on Nov 21, 2024.
How did Slate Path Capital LP's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Slate Path Capital LP has 0.
Where does Slate Path Capital LP file Form 4?
Slate Path Capital LP has filed Form 4 at KRSA (Cyclerion Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.